Research & Literature

Randomized Controlled Study to Evaluate the Efficacy of a Preoperative Respiratory Rehabilitation Program to Prevent Postoperative Pulmonary Complications after Esophagectomy.

Yamana I, Takeno S, Hashimoto T, et al.

Digestive surgery 2015; (32(5)):331-7 doi:10.1159/000434758.

Prevalence and predictors of anxiety and depression among esophageal cancer patients prior to surgery.

Hellstadius Y, Lagergren J, Zylstra J, et al.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2016; (29(8)):1128-1134 doi:10.1111/dote.12437.

Concurrent Therapy with a Low-carbohydrate Diet and Miglitol Remarkably Improved the Postprandial Blood Glucose and Insulin Levels in a Patient with Reactive Hypoglycemia due to Late Dumping Syndrome.

Hirose S, Iwahashi Y, Seo A, et al.

Internal medicine (Tokyo, Japan) 2016; (55(9)):1137-42 doi:10.2169/internalmedicine.55.5655.

Transthoracically or transabdominally: how to approach adenocarcinoma of the distal esophagus and cardia. A meta-analysis.

Aurello P, Magistri P, Berardi G, et al.

Tumori 2016; (102(4)):352-60 doi:10.5301/tj.5000517.

Esophageal Adenocarcinoma: Screening, Surveillance, and Management.

Mansour NM, Groth SS, Anandasabapathy S

Annual review of medicine 2017; (68()):213-227 doi:10.1146/annurev-med-050715-104218.

Efficacy of PET-CT in the Diagnosis and Treatment of Recurrence After Esophageal Cancer Surgery.

Kudou M, Shiozaki A, Fujiwara H, et al.

Anticancer research 2016; (36(10)):5473-5480 doi:10.21873/anticanres.11128.

[Treatment Strategy for Esophagogastric Junction Carcinoma;Highly Controversial Topic in the Upper Gastrointestinal Malignancy].

Yamashita H, Seto Y

Kyobu geka. The Japanese journal of thoracic surgery 2017; (70(1)):72-79.

Is endoscopic ultrasound examination necessary in the management of esophageal cancer?

DaVee T, Ajani JA, Lee JH

World journal of gastroenterology 2017; (23(5)):751-762 doi:10.3748/wjg.v23.i5.751.

Endoscopic ultrasonography compared with multidetector computed tomography for the preoperative staging of gastric cancer: a meta-analysis.

Nie RC, Yuan SQ, Chen XJ, et al.

World journal of surgical oncology 2017; (15(1)):113 doi:10.1186/s12957-017-1176-6.

Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030.

Arnold M, Laversanne M, Brown LM, et al.

The American journal of gastroenterology 2017; (112(8)):1247-1255 doi:10.1038/ajg.2017.155.

Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma.

Kauppila JH, Ringborg C, Johar A, et al.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2018; (21(3)):533-541 doi:10.1007/s10120-017-0761-2.

Esophagectomy versus endoscopic resection for patients with early-stage esophageal adenocarcinoma: A National Cancer Database propensity-matched study.

Marino KA, Sullivan JL, Weksler B

The Journal of thoracic and cardiovascular surgery 2018; (155(5)):2211-2218.e1 doi:10.1016/j.jtcvs.2017.11.111.

Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.

Schlottmann F, Molena D, Patti MG

Updates in surgery 2018; (70(3)):339-342 doi:10.1007/s13304-018-0564-y.

[Minimally invasive surgery in adenocarcinoma of esophagogastric junction].

Zang L, Li S, Zheng M

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2018; (21(8)):875-880.

Obesity and increased risk of esophageal adenocarcinoma.

Elliott JA, Donohoe CL, Reynolds JV

Expert review of endocrinology & metabolism 2015; (10(5)):511-523 doi:10.1586/17446651.2015.1077696.

Update on Endoscopy-Based Imaging Techniques in the Diagnosis of Esophageal Cancer.

Vasile MI, Mirea CS, Vîlcea ID, et al.

Current health sciences journal 2017; (43(4)):295-300 doi:10.12865/CHSJ.43.04.01.

Optimal management of gastroesophageal junction cancer.

Greally M, Agarwal R, Ilson DH

Cancer 2019; (125(12)):1990-2001 doi:10.1002/cncr.32066.

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.

Shitara K, Iwata H, Takahashi S, et al.

The Lancet. Oncology 2019; (20(6)):827-836 doi:10.1016/S1470-2045(19)30088-9.

Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.

Mitchell KG, Ikoma N, Nelson DB, et al.

The Annals of thoracic surgery 2019; (108(3)):845-851 doi:10.1016/j.athoracsur.2019.04.024.

True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends.

Kumamoto T, Kurahashi Y, Niwa H, et al.

Surgery today 2020; (50(8)):809-814 doi:10.1007/s00595-019-01843-4.

Barretts's carcinogenesis.

Mukaisho KI, Kanai S, Kushima R, et al.

Pathology international 2019; (69(6)):319-330 doi:10.1111/pin.12804.

Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma.

Nobel T, Molena D

Annals of gastroenterological surgery 2019; (3(4)):390-395 doi:10.1002/ags3.12268.

The Influence of the Perioperative Nutritional Status on the Survival Outcomes for Esophageal Cancer Patients with Neoadjuvant Chemotherapy.

Hikage M, Taniyama Y, Sakurai T, et al.

Annals of surgical oncology 2019; (26(13)):4744-4753 doi:10.1245/s10434-019-07742-9.

Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.

Yamashita K, Iwatsuki M, Harada K, et al.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020; (23(1)):95-104 doi:10.1007/s10120-019-00999-9.

Comparison Between Size and Stage of Preoperative Tumor Defined by Preoperative Magnetic Resonance Imaging and Postoperative Specimens After Radical Resection of Esophageal Cancer.

Gao Z, Hua B, Ge X, et al.

Technology in cancer research & treatment 2019; (18()):1533033819876263 doi:10.1177/1533033819876263.

Tumor location is an independent prognostic factor of esophageal adenocarcinoma based on the eighth edition of TNM staging system in Chinese patients.

Deng HY, Zheng X, Alai G, et al.

Annals of translational medicine 2019; (7(16)):365 doi:10.21037/atm.2019.01.84.

Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical.

Greally M, Ku GY

Journal of thoracic disease 2019; (11(Suppl 15)):S1855-S1860 doi:10.21037/jtd.2019.08.116.

Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers.

Hölscher AH, Law S

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020; (23(1)):3-9 doi:10.1007/s10120-019-01022-x.

Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction.

Cai MZ, Lv CB, Cai LS, Chen QX

Medicine 2019; (98(51)):e18451 doi:10.1097/MD.0000000000018451.

Predictors of Patient-Reported Reflux After Esophagectomy.

Hasan IS, Mahajan N, Viehman J, et al.

The Annals of thoracic surgery 2020; (110(4)):1160-1166 doi:10.1016/j.athoracsur.2020.03.127.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

Shitara K, Bang YJ, Iwasa S, et al.

The New England journal of medicine 2020; (382(25)):2419-2430 doi:10.1056/NEJMoa2004413.

[Mutltifaceted biological roles of adiponectin].

Cuerq C, Morineau G, Dufour-Rainfray D, et al.

Annales de biologie clinique 2020; (78(3)):243-252 doi:10.1684/abc.2020.1562.

Airway Management in Patients With a History of Esophagectomy: A Case Series.

Myoga Y

Journal of cardiothoracic and vascular anesthesia 2020; (34(11)):3063-3067 doi:10.1053/j.jvca.2020.06.048.

Visceral obesity and incident cancer and cardiovascular disease: An integrative review of the epidemiological evidence.

Silveira EA, Kliemann N, Noll M, et al.

Obesity reviews : an official journal of the International Association for the Study of Obesity 2021; (22(1)):e13088 doi:10.1111/obr.13088.

Transhiatal versus transthoracic surgical approach for Siewert type Ⅱ adenocarcinoma of the esophagogastric junction: a meta-analysis.

Wu H, Shang L, Du F, et al.

Expert review of gastroenterology & hepatology 2020; (14(11)):1107-1117 doi:10.1080/17474124.2020.1806710.

Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines.

Anker CJ, Dragovic J, Herman JM, et al.

International journal of radiation oncology, biology, physics 2021; (109(1)):186-200 doi:10.1016/j.ijrobp.2020.08.050.

Current and Future Treatment Strategies for Esophageal Adenocarcinoma.

Quaas A

Cancers 2020; (12(10)) doi:10.3390/cancers12102930.

Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance.

Cook MB, Thrift AP

Gastrointestinal endoscopy clinics of North America 2021; (31(1)):1-26 doi:10.1016/j.giec.2020.08.001.

Selected updates in molecular and genomic pathology of esophageal cancer.

Liu Y, Zhao L, Xue L, Hou Y

Annals of the New York Academy of Sciences 2020; (1482(1)):225-235 doi:10.1111/nyas.14527.

Visceral Obesity, Metabolic Syndrome, and Esophageal Adenocarcinoma.

Elliott JA, Reynolds JV

Frontiers in oncology 2021; (11()):627270 doi:10.3389/fonc.2021.627270.

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Kelly RJ, Ajani JA, Kuzdzal J, et al.

The New England journal of medicine 2021; (384(13)):1191-1203 doi:10.1056/NEJMoa2032125.

Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.

Mishima S, Shitara K

Expert opinion on biological therapy 2021; (21(7)):825-830 doi:10.1080/14712598.2021.1912007.

Concurrent diagnosis of anxiety increases postoperative length of stay among patients receiving esophagectomy for esophageal cancer.

Coffey MR, Bachman KC, Worrell SG, et al.

Psycho-oncology 2021; (30(9)):1514-1524 doi:10.1002/pon.5707.

Molecular phenotyping reveals the identity of Barrett's esophagus and its malignant transition.

Nowicki-Osuch K, Zhuang L, Jammula S, et al.

Science (New York, N.Y.) 2021; (373(6556)):760-767 doi:10.1126/science.abd1449.

Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial).

Tagkalos E, van der Sluis PC, Berlth F, et al.

BMC cancer 2021; (21(1)):1060 doi:10.1186/s12885-021-08780-x.

Limitations of Heartburn and Other Societies' Criteria in Barrett's Screening for Detecting De Novo Esophageal Adenocarcinoma.

Sawas T, Zamani SA, Killcoyne S, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022; (20(8)):1709-1718 doi:10.1016/j.cgh.2021.10.039.

Racial Disparities in Esophageal Cancer.

Pickens A

Thoracic surgery clinics 2022; (32(1)):57-65 doi:10.1016/j.thorsurg.2021.09.004.

Long-term outcomes of endoscopic mucosal resection for early-stage esophageal adenocarcinoma.

Oza K, Peesay T, Greenspun B, et al.

Surgical endoscopy 2022; (36(7)):5136-5143 doi:10.1007/s00464-021-08884-2.

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

Doki Y, Ajani JA, Kato K, et al.

The New England journal of medicine 2022; (386(5)):449-462 doi:10.1056/NEJMoa2111380.

The Immune Underpinnings of Barrett's-Associated Adenocarcinogenesis: a Retrial of Nefarious Immunologic Co-Conspirators.

Tambunting L, Kelleher D, Duggan SP

Cellular and molecular gastroenterology and hepatology 2022; (13(5)):1297-1315 doi:10.1016/j.jcmgh.2022.01.023.

Increasing Use of PET-CT, Neoadjuvant Treatment, Minimally Invasive Approach and Surgical Radicality in Esophageal Cancer Surgery are Associated with Improved Short- and Long-term Outcomes in Real-World Setting.

Junttila A, Saviaro H, Huhta H, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2022; (26(4)):742-749 doi:10.1007/s11605-022-05279-z.

Clinicopathological features and prognosis of gastric tube cancer after esophagectomy for esophageal cancer: a nationwide study in Japan.

Ota M, Morita M, Ikebe M, et al.

Esophagus : official journal of the Japan Esophageal Society 2022; (19(3)):384-392 doi:10.1007/s10388-022-00915-8.

Barrett's esophagus stages: their correlation with SBS17-associated DNA mutations and the identification of histological marker genes.

Busslinger GA

Molecular & cellular oncology 2022; (9(1)):2026559 doi:10.1080/23723556.2022.2026559.

Immunotherapy in Squamous Cell Cancer of the Esophagus.

Thuss-Patience P, Stein A

Current oncology (Toronto, Ont.) 2022; (29(4)):2461-2471 doi:10.3390/curroncol29040200.

Esophageal adenocarcinoma: A dire need for early detection and treatment.

Joseph A, Raja S, Kamath S, et al.

Cleveland Clinic journal of medicine 2022; (89(5)):269-279 doi:10.3949/ccjm.89a.21053.

Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy.

Zhang X, Wang Y, Meng L

Acta pharmaceutica Sinica. B 2022; (12(3)):1054-1067 doi:10.1016/j.apsb.2021.09.028.

Impact of Robotic Approach on Post-Anastomotic Leaks After Esophagectomy for Esophageal Cancer.

Wu J, Putnam LR, Silva JP, et al.

The American surgeon 2022; (88(10)):2499-2507 doi:10.1177/00031348221101515.

Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction.

Zheng YH, Zhao EH

World journal of gastroenterology 2022; (28(31)):4299-4309 doi:10.3748/wjg.v28.i31.4299.

Ongoing Controversies in Esophageal Cancer II: Gastrectomy versus Esophagectomy for Siewert Type II Esophageal Adenocarcinoma.

Devaud N, Carroll P

Thoracic surgery clinics 2022; (32(4)):553-563 doi:10.1016/j.thorsurg.2022.07.004.

The role of endoscopic resection in early-stage esophageal adenocarcinoma: Esophagectomy is associated with improved survival in patients presenting with clinical stage T1bN0 disease.

Swanson J, Littau M, Tonelli C, et al.

Surgery 2023; (173(3)):693-701 doi:10.1016/j.surg.2022.08.042.

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.

Shah MA, Kennedy EB, Alarcon-Rozas AE, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(7)):1470-1491 doi:10.1200/JCO.22.02331.

Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing.

Lavacchi D, Fancelli S, Buttitta E, et al.

International journal of molecular sciences 2023; (24(5)) doi:10.3390/ijms24054877.

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Ajani JA, D'Amico TA, Bentrem DJ, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(4)):393-422 doi:10.6004/jnccn.2023.0019.

Multiple staging investigations may not change management in patients with high-grade dysplasia or early esophageal adenocarcinoma.

Reyhani A, Gimson E, Baker C, et al.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2023; (36(10)) doi:10.1093/dote/doad020.

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.

Shitara K, Lordick F, Bang YJ, et al.

Lancet (London, England) 2023; (401(10389)):1655-1668 doi:10.1016/S0140-6736(23)00620-7.

Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.

Kim Y, Yamamoto S, Kato K

Cancer management and research 2023; (15()):399-406 doi:10.2147/CMAR.S390499.

Therapeutic Advances in the Treatment of Gastroesophageal Cancers.

Li JJ, Rogers JE, Yamashita K, et al.

Biomolecules 2023; (13(5)) doi:10.3390/biom13050796.

Systematic review of quality of life after esophagectomy and total gastrectomy in patients with gastro-esophageal junction cancer.

Walmsley J, Ariyarathenam A, Berrisford R, et al.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2023; (36(12)) doi:10.1093/dote/doad039.

Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers.

Cetin B, Wabl CA, Gumusay O

Immunotherapy 2023; (15(12)):945-962 doi:10.2217/imt-2022-0287.

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.

Van Cutsem E, di Bartolomeo M, Smyth E, et al.

The Lancet. Oncology 2023; (24(7)):744-756 doi:10.1016/S1470-2045(23)00215-2.

Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives.

Sato Y, Okamoto K, Kawano Y, et al.

Journal of clinical medicine 2023; (12(14)) doi:10.3390/jcm12144646.

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

Shah MA, Shitara K, Ajani JA, et al.

Nature medicine 2023; (29(8)):2133-2141 doi:10.1038/s41591-023-02465-7.

Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma.

Bao C, Tourdot RW, Brunette GJ, et al.

Nature communications 2023; (14(1)):6203 doi:10.1038/s41467-023-41805-6.

Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis.

Saha B, Vantanasiri K, Mohan BP, et al.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024; (22(7)):1381-1394.e7 doi:10.1016/j.cgh.2023.10.006.

Patients With Esophageal Adenocarcinoma With Prior Gastroesophageal Reflux Disease Symptoms Are Similar to Those Without Gastroesophageal Reflux Disease: A Cross-Sectional Study.

Chandar AK, Keerthy K, Gupta R, et al.

The American journal of gastroenterology 2024; (119(5)):823-829 doi:10.14309/ajg.0000000000002593.

Esophageal cancer - the utility of PET/CT in staging prior to chemoradiation.

Deja A, Włodarczyk M

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology 2023; (28(5)):608-611 doi:10.5603/rpor.96869.

Prevalence and associated factors of worry for cancer in patients with a Barrett's esophagus.

van der Ende-van Loon MCM, Oude Nijhuis RAB, Curvers WL, Schoon EJ

Scientific reports 2024; (14(1)):2878 doi:10.1038/s41598-024-53428-y.

Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.

Fick CN, Dunne EG, Sihag S, et al.

The Annals of thoracic surgery 2024; (118(1)):130-140 doi:10.1016/j.athoracsur.2024.02.021.

Esophageal cancer: Treatment advances and need for screening.

Eisner DC

JAAPA : official journal of the American Academy of Physician Assistants 2024; (37(4)):19-24 doi:10.1097/01.JAA.0001007328.84376.da.

Reevaluating Adiponectin's impact on obesity hypertension: a Chinese case-control study.

Wu O, Lu X, Leng J, et al.

BMC cardiovascular disorders 2024; (24(1)):208 doi:10.1186/s12872-024-03865-4.

The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.

Li JB, Lai MY, Lin ZC, et al.

Cancer immunology, immunotherapy : CII 2024; (73(7)):132 doi:10.1007/s00262-024-03726-1.

Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma.

Kadono T, Yamamoto S, Kato K

Future oncology (London, England) 2024; (20(28)):2097-2107 doi:10.1080/14796694.2024.2345043.

Etiologic factors for Barrett's esophagus: toward countermeasures in Asia.

Iijima K

Expert review of gastroenterology & hepatology 2024; (18(8)):407-420 doi:10.1080/17474124.2024.2386367.

Optimizing Recovery: A Comprehensive Case Report on Physiotherapy Rehabilitation in Esophagectomy Patients.

Dave AR, Fating TB

Cureus 2024; (16(6)):e63473 doi:10.7759/cureus.63473.

Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting.

Zhou KI, Strickler JH, Chen H

Journal of hematology & oncology 2024; (17(1)):73 doi:10.1186/s13045-024-01595-w.

Invited Editorial on "Occurrence of Dumping Syndrome After Esophageal Cancer Surgery: Systematic Review and Meta-Analysis" by Lin et al.

Stewart CL

Annals of surgical oncology 2025; (32(2)):634-635 doi:10.1245/s10434-024-16289-3.

Current Standards and Controversies in Multidisciplinary Management of Locoregional Gastroesophageal Junction Tumors.

Santos ET, Baig D, Sanford NN

Current oncology reports 2024; (26(12)):1606-1611 doi:10.1007/s11912-024-01606-6.

PD-L1 thresholds predict efficacy of immune checkpoint inhibition in first-line treatment of advanced gastroesophageal adenocarcinoma. A systematic review and meta-analysis of seven phase III randomized trials.

Formica V, Morelli C, Fornaro L, et al.

ESMO open 2024; (9(11)):103967 doi:10.1016/j.esmoop.2024.103967.

Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.

Aoki Y, Nakayama I, Shitara K

Current oncology reports 2025; (27(1)):15-29 doi:10.1007/s11912-024-01626-2.

Evolving Strategies in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Esophagogastric Adenocarcinoma.

Balmaceda NB, Kim SS

Current oncology reports 2025; (27(2)):81-94 doi:10.1007/s11912-024-01624-4.

Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.

Hoeppner J, Brunner T, Schmoor C, et al.

The New England journal of medicine 2025; (392(4)):323-335 doi:10.1056/NEJMoa2409408.

Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands.

van Laarhoven H, Verhoeven R, van Berge Henegouwen M, et al.

EClinicalMedicine 2025; (80()):103067 doi:10.1016/j.eclinm.2024.103067.

Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.

Marabelle A, O'Malley DM, Hendifar AE, et al.

Nature cancer 2025; (6(2)):253-258 doi:10.1038/s43018-024-00894-y.

A novel framework for esophageal cancer grading: combining CT imaging, radiomics, reproducibility, and deep learning insights.

Alsallal M, Ahmed HH, Kareem RA, et al.

BMC gastroenterology 2025; (25(1)):356 doi:10.1186/s12876-025-03952-6.

Temporal Trends and Sex Differences in the Incidence of Esophageal Squamous Cell Carcinoma and Adenocarcinoma from CI5 VIII-XII Data - Global, 1993-2017.

Li J, Sun K, Zhu Q, et al.

China CDC weekly 2025; (7(15)):491-496 doi:10.46234/ccdcw2025.082.

Four-step formula for the Siewert classification of adenocarcinomas of the esophagogastric junction: a computed tomography-based quantitative model.

Liu YT, Li YA, Li JZ, et al.

Expert review of medical devices 2025; (22(7)):747-755 doi:10.1080/17434440.2025.2510534.

Guidelines of Onkopedia: What Is New?

Scheck MK, Al-Batran SE, Borner M, et al.

Oncology research and treatment 2025; (48(10)):655-662 doi:10.1159/000546550.

Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy.

Hoeppner J, Schmoor C, Brunner T, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(32)):3451-3456 doi:10.1200/JCO-25-00948.

Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW.

Stratton SP, Pang L, Pugh J, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2025; (38(12)):100844 doi:10.1016/j.modpat.2025.100844.

Clinical Pharmacology Profile of the Claudin 18.2 Antibody Zolbetuximab.

Yang J, Yamada A, Shitara K, et al.

Clinical pharmacokinetics 2025; (64(10)):1465-1476 doi:10.1007/s40262-025-01552-x.

Metachronous esophageal squamous cell carcinoma suspected as a second malignancy arising at the site of post-radiotherapy for esophageal adenocarcinoma.

Furusawa H, Hayashi T, Okamoto K, et al.

Clinical journal of gastroenterology 2025; (18(6)):1068-1073 doi:10.1007/s12328-025-02208-w.

Immune checkpoint inhibitors with trastuzumab and chemotherapy in advanced HER2-positive gastric cancer: A systematic review and meta-analysis.

de Moraes FCA, Moreira Rego LHR, de Paiva FA, et al.

Critical reviews in oncology/hematology 2025; (216()):104975 doi:10.1016/j.critrevonc.2025.104975.

Strategies to prevent Barrett's esophagus associated esophageal adenocarcinoma.

Singh DM, Trindade AJ

World journal of gastroenterology 2025; (31(39)):108853 doi:10.3748/wjg.v31.i39.108853.

Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma.

Thrift AP, Kendall BJ

Gastrointestinal endoscopy clinics of North America 2026; (36(1)):49-68 doi:10.1016/j.giec.2025.05.006.

Role of Endoscopy in the Diagnosis and Management of Esophageal Cancer.

Ma J, Pan S, Mortan R, et al.

Journal of clinical medicine 2025; (14(22)) doi:10.3390/jcm14228169.

The metabolic profile of lean patients with esophageal adenocarcinoma and Barrett's esophagus.

Sawas T, Benson JT, Allen A, et al.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2025; (38(6)) doi:10.1093/dote/doaf080.

Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience.

Shimozaki K, Ooki A, Fukuoka S, et al.

Journal of cancer research and clinical oncology 2025; (152(1)):16 doi:10.1007/s00432-025-06406-4.

Nutritional approach to dumping syndrome.

Scarpellini E, Siquini W

Best practice & research. Clinical gastroenterology 2025; (79()):102075 doi:10.1016/j.bpg.2025.102075.

Understanding divergent outcomes: A comparative analysis of ESOPEC and CROSS real-world studies in esophageal adenocarcinoma.

Burri P, Chatziisaak S, Wolf S, Chatziisaak D

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2026; (52(2)):111374 doi:10.1016/j.ejso.2025.111374.

An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1).

Seguchi K, Kawazoe A, Nakayama I, Shitara K

Expert review of anticancer therapy 2026; 1-10 doi:10.1080/14737140.2026.2628069.

Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice.

Shimozaki K, Ooki A, Yamahata Y, et al.

ESMO gastrointestinal oncology 2025; (7()):100128 doi:10.1016/j.esmogo.2024.100128.

Glucocorticoid Therapy and Miglitol Ameliorate Reactive Hypoglycemia Secondary to Late Dumping Syndrome: A Case Report.

Saito M, Uchino H, Yoshida A, et al.

Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.6534-25.

Claudin18.2 promote gastric cancer proliferation by activating MCM2/5.

Zheng B, Fu M, Lou F, et al.

Scientific reports 2026; (16(1)).